glp-1 obesity drugs pipeline Market Overview: Agonists and the Market | Blog A Beginner's Guide to Investing

Another update recommends considering glucagonlike peptide1 [GLP1] receptor agonists for highrisk patients with CVD who have type 2 diabetes, which is in line with the findings of recently published clinical trials, including the LEADER (ClinicalTrials.gov identifier: NCT01179048) trials 2

When it is combined with other diabetes medications, particularly insulin and insulin secretagogues, hypoglycemia can occur

Feng, G

speakers bureau and consulting fees from Amgen, Aegerion, Sanofi, and Regeneron until April 2019 (fees paid to the academic institution)

Recent clinical trials demonstrated that SGLT2 inhibitors and GLP-1RAs bring beneficial effects on the cardiorenal outcomes of T2D subjects who are at high risk for CVD